NEW YORK (GenomeWeb) – The National Institutes of Health this month awarded more than $1.1 million to fund three research projects related to a gene silencing-based treatment for amyotrophic lateral sclerosis (ALS), the role of RNAi in mammalian antiviral responses, and the effects of a specific microRNA in diabetes-associated cancer, respectively.

The first grant was awarded to University of Massachusetts researcher and RXi Pharmaceuticals collaborator Robert Brown to support his efforts to develop and test an miRNA-based expression system to treat a heritable form of ALS.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.